PEPITEM Regulates the Synovial Microenvironment During Immune-Mediated Inflammatory Arthritis to Limit Disease - Scorecard - MDSpire

PEPITEM Modulates the Synovial Environment in Immune-Mediated Inflammatory Arthritis to Mitigate Disease Progression

  • By

  • Mussarat Wahid

  • Samuel Kemble

  • Oladimeji Abudu

  • Anella Saviano

  • Christopher Mahony

  • Jonathan W. Lewis

  • Thomas A. Nicholson

  • Anna Schettino

  • Noemi Marigliano

  • Kathryn Frost

  • Jenefa Begum

  • Alyssa M. Urbanowski

  • Marion Limo

  • Rakesh Jha

  • Sandra Martinez Jarquin

  • Laleh Pezhman

  • Abbie E. A. Degan

  • Amy E. Anderson

  • Charlotte G. Smith

  • Armaiti Batki

  • Holly Adams

  • Francesco Caso

  • Raffaele Scarpa

  • Iain McInnes

  • Stefan Siebert

  • Arthur G. Pratt

  • Andrew Filer

  • Karim Raza

  • Adam P. Croft

  • Myriam Chimen

  • Felicity de Cogan

  • G. Ed Rainger

  • Asif J. Iqbal

  • Francesco Maione

  • Helen M. McGettrick

  • July 1, 2026

Share

Clinical Scorecard: PEPITEM Modulates the Synovial Environment in Immune-Mediated Inflammatory Arthritis to Mitigate Disease Progression

At a Glance

CategoryDetail
ConditionImmune-Mediated Inflammatory Diseases (IMIDs)
Key MechanismsModulation of leukocyte trafficking and restoration of regulatory pathways via PEPITEM.
Target PopulationPatients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and other IMIDs.
Care SettingClinical management of inflammatory arthritis.

Key Highlights

  • PEPITEM levels are diminished in patients with IMIDs.
  • Supplementation of PEPITEM can limit leukocyte migration and disease severity in murine models.
  • Adiponectin influences PEPITEM secretion and may play a role in RA pathology.
  • Current treatments do not restore endogenous regulatory pathways.
  • PEPITEM replacement therapy may offer a new therapeutic avenue.

Guideline-Based Recommendations

Diagnosis

  • Use established criteria for classification of RA and PsA.

Management

  • Consider PEPITEM replacement therapy for patients with RA.

Monitoring & Follow-up

  • Monitor levels of PEPITEM and adiponectin in patients.

Risks

  • Potential for adverse effects from modulation of leukocyte trafficking.

Patient & Prescribing Data

Patients >18 years of age with suspected inflammatory arthritis.

Patients were DMARD and glucocorticoid naive at enrollment.

Clinical Best Practices

  • Assess the adiponectin–PEPITEM pathway in patients across different disease phases.
  • Utilize appropriate classification criteria for accurate diagnosis.

Related Resources & Content

Original Source(s)

PEPITEM Regulates the Synovial Microenvironment During Immune-Mediated Inflammatory Arthritis to Limit Disease

  • by Mussarat Wahid, Samuel Kemble, Oladimeji Abudu, Anella Saviano, Christopher Mahony, Jonathan W. Lewis, Thomas A. Nicholson, Anna Schettino, Noemi Marigliano, Kathryn Frost, Jenefa Begum, Alyssa M. Urbanowski, Marion Limo, Rakesh Jha, Sandra Martinez Jarquin, Laleh Pezhman, Abbie E. A. Degan, Amy E. Anderson, Charlotte G. Smith, Armaiti Batki, Holly Adams, Francesco Caso, Raffaele Scarpa, Iain McInnes, Stefan Siebert, Arthur G. Pratt, Andrew Filer, Karim Raza, Adam P. Croft, Myriam Chimen, Felicity de Cogan, G. Ed Rainger, Asif J. Iqbal, Francesco Maione, Helen M. McGettrick

  • July 1, 2026

Related Content

Autoreactivity vs autoimmunity: characteristics of autoantigen-specific CD4 T-cells in rheumatoid arthritis and health.

Immune network dysregulation in rheumatoid arthritis and systemic lupus erythematosus: cytokine signatures, autoantibody profiles, and implications for precision medicine

When Bad Data Enters the Drug Pipeline

Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.